IP Library Granted Patent US 9,737,524
Granted Patent B2
US 9,737,524 · App. 14/860,057 · Granted Aug 22, 2017

Prophylactic and/or therapeutic agent for mild cognitive impairment

Inventors: Masafumi Ihara (Hyogo, JP); Takakuni Maki (Hyogo, JP); Akihiko Taguchi (Hyogo, JP)
Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION
A61K31/4709A61K9/0019A61K9/14C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,737,524
App. No.
14/860,057
Granted
Aug 22, 2017
Kind
B2
Abstract

Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Down's syndrome, or macular degeneration.

Claims (7)

1. A method for treating a patient having a mild cognitive impairment and a mini-mental state examination score from 22 to 26, comprising:

administering an effective amount of an agent comprising cilostazol to the patient,

wherein the method does not comprise administering donepezil to the patient.

2. The method of claim 1 , wherein the patient's mini-mental state examination score is increased by about 4 after the administration.

3. A method for treating a patient having a mild cognitive impairment and a mini-mental state examination score from 22 to 26, comprising:

administering an effective amount of an agent consisting of cilostazol and at least one pharmaceutical product carrier selected from the group consisting of a binder, a disintegrator, a lubricant, and a plasticizer to the patient,

wherein the method does not comprise administering donepezil to the patient.

Assignments (1)
CHANGE OF NAME Recorded Feb 19, 2019
From: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION
To: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Reel/Frame 048374/0472 →
Priority Claims (2)
JP 2012-135906 · Jun 15, 2012 · national
JP 2012-223580 · Oct 5, 2012 · national
Continuity (2)
Continuation 14407692
Related Publication 20160008348A1 · Jan 14, 2016